Joint repair using mesenchymal stem cells

Patent metadata

Field	Value
Publication number	US-9050178-B2
Application number	US-201313743004-A
Country	US
Kind code	B2
Filing date	Jan 16, 2013
Priority date	Apr 25, 2000
Publication date	Jun 9, 2015
Grant date	Jun 9, 2015

Abstract

A method of repairing and/or stabilizing a joint by administering mesenchymal stem cells to the joint. Such a method provides for the regeneration of cartilaginous tissue in the joint, including meniscal tissue.

First claim

The invention claimes is:

1. A method of repairing damaged meniscal tissue in a joint of a human, comprising:
administering directly to said joint via intra-articular injection a liquid suspension comprising isolated allogeneic mesenchymal stem cells and an acceptable pharmaceutical carrier in an amount effective to repair damaged meniscal tissue in a joint of the animal, wherein the mesenchymal stem cells differentiate into and/or stimulate production of meniscal tissue,
wherein the suspension is administered in the absence of a scaffold and wherein the pharmaceutical carrier is saline.

2. The method of claim 1 , wherein said mesenchymal stem cells differentiate into meniscal tissue.

3. The method of claim 1 , wherein said suspension does not contain hyaluronan or a hyaluronic acid derivative.

4. The method of claim 1 , wherein said joint is selected from the group consisting of knee, shoulder, and temporal mandibular joints.

5. The method of claim 1 , wherein the mesenchymal stem cells are present in the liquid suspension in an amount of from about 1×10 4 cells to about 1.5×10 8 cells.

6. A method of reducing joint pain in a human, comprising:
administering via intra-articular injection a liquid suspension comprising isolated allogeneic mesenchymal stem cells and an acceptable pharmaceutical carrier in an amount effective to reduce joint pain, wherein the mesenchymal stem cells differentiate into and/or stimulate production of meniscal tissue, wherein the suspension is administered in the absence of a scaffold and wherein the pharmaceutical carrier is saline.

7. The method of claim 6 , wherein said mesenchymal stem cells regenerate meniscal tissue between opposing bone or osteochondral surfaces.

8. The method of claim 6 , wherein said suspension does not contain hyaluronan or a hyaluronic acid derivative.

9. The method of claim 6 , wherein said joint is selected from the group consisting of knee, shoulder, and temporal mandibular joints.

10. The method of claim 6 , wherein the mesenchymal stem cells are present in the liquid suspension in an amount of from about 1×10 4 cells to about 1.5×10 8 cells.

11. A method of preventing osteoarthritis at a site damaged by meniscal injury in a human, comprising:
administering via intra-articular injection a liquid suspension comprising isolated allogeneic mesenchymal stem cells and an acceptable pharmaceutical carrier in an amount effective to prevent osteoarthritis at the site, wherein the mesenchymal stem cells differentiate into and/or stimulate production of meniscal tissue, wherein the suspension is administered in the absence of a scaffold and wherein the pharmaceutical carrier is saline.

12. The method of claim 11 , wherein said mesenchymal stem cells regenerate meniscal tissue between opposing bone or osteochondral surfaces.

13. The method of claim 11 , wherein said suspension does not contain hyaluronan or a hyaluronic acid derivative.

14. The method of claim 11 , wherein said site is selected from the group consisting of knee, shoulder, and temporal mandibular joints.

15. The method of claim 11 , wherein the mesenchymal stem cells are present in the liquid suspension in an amount of from about 1×10 4 cells to about 1.5×10 8 cells.

16. A method of protecting articular cartilage at a site damaged by meniscal injury in a human, comprising:
administering via intra-articular injection a liquid suspension comprising isolated allogeneic mesenchymal stem cells and an acceptable pharmaceutical carrier in an amount effective to protect articular cartilage at the site, wherein the mesenchymal stem cells differentiate into and/or stimulate production of meniscal tissue, wherein the suspension is administered in the absence of a scaffold and wherein the pharmaceutical carrier is saline.

17. The method of claim 16 , wherein said suspension does not contain hyaluronan or a hyaluronic acid derivative.

18. The method of claim 16 , wherein said site is selected from the group consisting of knee, shoulder, and temporal mandibular joints.

19. A method of reducing osteophyte formation at a site damaged by meniscal injury in a human, comprising:
administering via intra-articular injection a liquid suspension comprising isolated allogeneic mesenchymal stem cells and an acceptable pharmaceutical carrier in an amount effective to reduce osteophyte formation at the site, wherein the mesenchymal stem cells differentiate into and/or stimulate production of meniscal tissue, wherein the suspension is administered in the absence of a scaffold and wherein the pharmaceutical carrier is saline.

20. The method of claim 19 , wherein said suspension does not contain hyaluronan or a hyaluronic acid derivative.

21. The method of claim 19 , wherein said site is selected from the group consisting of knee, shoulder, and temporal mandibular joints.

Assignees

• Osiris Therapeutics Inc
• Mesoblast Internat S Rl

Inventors

• Barry Francis P
• Murphy J Mary
• Deans Robert
• Fink David J
• Moseley Annemarie

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61K35/12

  Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00) · CPC title

• A61F2/30756 Primary

  Cartilage endoprostheses (A61F2/3603 takes precedence) · CPC title

• A61K2035/124

  the cells being hematopoietic, bone marrow derived or blood cells · CPC title